Thrombocytosis and recurrent hepatic outflow obstruction (Budd-Chiari syndrome) after successful thrombolysis: case report and literature review.
Approximately two thirds of cases of hepatic flow obstruction are due to myeloproliferative disorders. Restoration of hepatic blood flow is the essential goal of treatment. Thrombolytic therapy seems to achieve good results at least in selected cases. A 32-year-old woman is presented, with an intermittent increase in platelet count (526-725 x 10(9)/L), two previous spontaneous abortions and acute symptomatic occlusion of hepatic veins, and in whom a diagnosis of essential thrombocythemia was initially carried out in agreement with the polycythemia vera study group criteria. She received recombinant tissue plasminogen activator followed by heparin with restoration of normal hepatic outflow. Asymptomatic re-occlusion of the hepatic veins was observed 1 year later, despite adequate continuous warfarin treatment. Angiography showed marked narrowing of the intrahepatic cava vein due to extrinsic compression by an enlarged liver, not due to a new thrombosis so that no specific intervention could be performed. In the presence of a dearly documented hepatic vein thrombosis, thrombolytic therapy should be considered. The patient was given low-molecular-weight heparin with a dramatic reduction in previously elevated fibrinogen level and a good control of the hepatic function.
Randi
Maria Luigia
ML
Department of Medical and Surgical Sciences, University of Padua Medical School, Padua, Italy. marialuigia.randi@unipd.it
Sartori
Maria Teresa
MT
Luzzatto
Guido
G
Ruzzon
Elisabetta
E
Boccagni
Patrizia
P
Ragazzi
Roberto
R
Girolami
Antonio
A
D000328:Adult; D006502:Budd-Chiari Syndrome / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D012008:Recurrence; D013922:Thrombocytosis / Q000175:diagnosis / Q000188:drug therapy*; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D016896:Treatment Outcome
D006493:Heparin; D010959:Tissue Plasminogen Activator